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Abstract
Medicine-related research includes numerous studies on the hazards of mortality and what risk
factors are associated with these hazards, such as diseases and treatments. These hazards are esti-
mated in a sample of people and summarised over the observed period. From these observations,
inferences can be made about the underlying population and consequently inform medical guidelines
for intervention. New health interventions are usually based on these estimated hazards obtained
from clinical trials. A lengthy lead time would be needed to observe their effect on population
longevity. This paper shows how estimated mortality hazards can be translated to hypothetical
changes in life expectancies at the individual and population levels. For an individual, the relative
hazards are translated into the number of years gained or lost in “effective age”, which is the average
chronological age with the same risk proﬁle. This translation from hazard ratio to effective age could
be used to explain to individuals the consequences of various diseases and lifestyle choices and as a
result persuade clients in life and health insurance to pursue a healthier lifestyle. At the population
level, a period life expectancy is a weighted average of component life expectancies associated with
the particular risk proﬁles, with the weights deﬁned by the prevalences of the risk factor of interest
and the uptake of the relevant intervention. Splitting the overall life expectancy into these compo-
nents allows us to estimate hypothetical changes in life expectancy at the population level at different
morbidity and uptake scenarios. These calculations are illustrated by two examples of medical
interventions and their impact on life expectancy, which are beta blockers in heart attack survivors
and blood pressure treatment in hypertensive patients. The second example also illustrates the
dangers of applying the results from clinical trials to much wider populations.
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1. Introduction
Survival analysis entails analysing data on the length of time until occurrence of an event, such as the
time to death (Therneau & Grambsch, 2000). A survival model is a regression model ﬁtted on the
data and estimates the time to an event based on several risk factors, such as sociodemographic
factors, lifestyle factors, medical conditions, and medical interventions (Therneau & Grambsch,
2000). This type of research is typically done in the medical ﬁeld. Survival models are of interest to
clinicians, because they can identify speciﬁc patient characteristics associated with different survival
rates. These ﬁndings can be used to counteract the harmful effects and enhance the protective effects
*Correspondence to: Elena Kulinskaya, School of Computing Sciences, Sciences 2.03, University of East Anglia,
Norwich Research Park, Norwich NR4 7TJ, UK. Tel: +44 (0)1603 59 2692. E-mail: E.Kulinskaya@uea.ac.uk
1
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1357321719000059
Downloaded from https://www.cambridge.org/core. UCL, Institute of Education, on 24 Jun 2019 at 14:35:33, subject to the Cambridge Core terms of use, available at
of modiﬁable risk factors, for example, blood pressure could be targeted to improve survival pro-
spects.
Survival models could also be of interest in retirement planning, life and health insurance, and
pensions. The key information in retirement planning is life expectancy at the individual and
population levels. Current life expectancy and future projections can inform individuals about how
to spend their pension pot during retirement, inform actuaries about pricing of annuities and life
insurance, and inform governments about taxation, national insurance rates, and pensions.
At an individual level, survival models that allow for differences in risk factors enable estimates of
life expectancy to be tailored for that individual rather than assuming an aggregate population
ﬁgure. This can help that individual with retirement planning, or help an underwriter to offer the
appropriate rate for an enhanced annuity. Indeed, “effective ages” are often used by insurers as a
way of applying the correct rating to an underwritten life.
Insurers, pensions providers and others are often interested in projecting life expectancies for a sub-
population that is different from the population as a whole, for example, by socioeconomic group or,
for an underwritten sub-population, by health status. This can lead to basis risk which can be
reduced by using survival models that allow for factors that differ between the sub-population and
the population. The examples below describe this in terms of two medical interventions. Gitsels et al.
(2017) present models that also allow for socioeconomic differences in the prevalence of treatments
via Mosaic categories. Applying the methods described in this paper can help to understand the
extent that differences in mortality improvements between a population and a sub-population can be
explained by differences in anti-hypertensive drug prescription, for example, and to project
improvements with more conﬁdence.
Changes in life expectancies can be calculated from the survival models estimated hazard ratios of
all-cause mortality. The tools needed for this calculation are a survival model, information on the
prevalence of the risk factor of interest, and a life table.
First, we provide some background on Cox’s proportional hazards survival models and the meaning
of a hazard ratio. Next, we show how estimated hazards of mortality associated with risk factors can
be translated to changes in life expectancies at the individual and population levels using an
“effective age” and period life expectancies. This will be illustrated by two examples of medical
interventions and their associated impact on life expectancy: beta blockers, a type of blood pressure
treatment, in heart attack survivors, and overall blood pressure treatment in hypertensive patients.
Using data from a UK primary care database, the survival models are estimated at different retire-
ment ages. The estimated hazard ratios are translated to changes in life expectancies at the individual
and population levels for men and women at ages 60, 65, 70, and 75 in the United Kingdom.
2. Hazard Ratio
The type of regression model typically used in survival analysis in medicine is the Cox’s proportional
hazards regression model (Therneau & Grambsch, 2000). The “hazard of mortality” is also com-
monly referred to as “force of mortality” and “mortality intensity”.
L. A. Gitsels et al.
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The Cox’s model estimates the hazard μi(x) for subject i at time x by multiplying the baseline hazard
function μ0(x) by the subject’s risk score ri (Therneau & Grambsch, 2000):
μi x; β;Zið Þ= μ0 xð Þri β;Zið Þ= μ0 xð ÞeβZi
The risk score is dependent of the values of the multiple risk factors Z and their coefﬁcients β. Taking
a ratio of the hazard functions for two subjects i and j who differ in one risk factor z and not in the
other risk factors, the coefﬁcient βz or the hazard ratio eβz per unit increase of risk factor z can be
calculated (Therneau & Grambsch, 2000):
μ x; β;Zð Þ= μi x; β;Zið Þ
μj x; β;Zj
  = μ0 xð Þe
βZ1
μ0 xð ÞeβZ0
=
eβzz1
eβzz0
= eβzðz0z1Þ
This means that the baseline hazard μ0(x) does not have to be speciﬁed and the hazard ratio eβz is
constant with respect to time x. In other words, the Cox’s model does not make any assumptions
about the shape of the baseline hazard function, but does assume proportional hazards for the risk
factors over time x. The time x may be age, or the time from the study entry. The assessment of the
proportional hazards assumption can be done visually by, for example, Kaplan–Meier plots or
numerically by, for example, the Grambsch and Therneau’s test (Therneau & Grambsch, 2000). This
test statistic can be interpreted as a measure of the correlation between the residuals from the model
and event times. If the proportional hazards assumption is violated, the risk factor should be spe-
ciﬁed differently by, for example, specifying time-dependent effects where follow-up time is split in
intervals in which the proportional hazards assumption holds.
An adjusted hazard ratio of mortality is interpreted as the instantaneous increased or decreased
hazard of mortality associated with a unit change from the reference value of the risk factor adjusted
for the other risk factors averaged over the length of the study period. In case of a binary risk factor
where absence is the reference value, then a hazard ratio <1 (i.e. a negative estimated coefﬁcient bβz)
means that the presence of the risk factor is associated with a decreased hazard of mortality and a
longer survival time. Similarly, a hazard ratio >1 (i.e. a positive estimated coefﬁcient bβz) means that
the presence of the risk factor is associated with an increased hazard of mortality and a shorter
survival time.
3. Effective Age
A hazard ratio of mortality is a relative term indicating how much better or worse off a person with a
risk factor is compared to a person without the risk factor with respect to their instantaneous hazard
of death. This relative term can be difﬁcult to comprehend. In some contexts, in medicine as well as
in insurance, a probability of seeing a certain event in some group is called risk, while the term
incidence is used in epidemiology. Hence, the risk ratio, or relative risk, often is the effect measure of
choice. Since the hazard ratio is also a relative measure, sometimes it is mistakenly interpreted as
relative risk. However, the hazard ratio is the ratio of the forces of mortality at a time x, whereas the
relative risk is the ratio of the probabilities of death over an interval from 0 to x.
To facilitate the understanding of the hazard ratio, in recent years medical research has presented
hazards also as the difference in the chronological age and the “effective age”, which is the average
age with the same hazard (Spiegelhalter, 2016). This difference in ages indicates “premature ageing”
if the effective age is higher than the chronological age or “rejuvenation” if the effective age is lower
than the chronological age, see Figure 1.
Medical advances and future longevity
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The difference between the chronological and effective ages can also be expressed as the number of
years gained or lost in age due to the unit change in risk factor. For simplicity, consider a binary risk
factor where absence is the reference value (z= 0) and presence is the unit change (z= 1). The
translation from a hazard of mortality to the number of years gained or lost in age is based on the
condition that there are proportional hazards as assumed by the Cox’s model and the condition that
the baseline hazard rate of a population increases linearly with age x on the log scale (Spiegelhalter,
2016). These conditions can be expressed as the hazard of mortality μ(x) being equal to the hazard
associated with the risk factor eβz and the hazard associated with ageing eα+ γx, μ(x)= eβz + α+ γx.
That is, the baseline Gompertz’ survival distribution is assumed for this calculation. Then, the
number of years gained or lost in age x is the log of hazard ratio eβ divided by the log of increase in
annual hazard rate in a population eγ, Δx= β/γ.
As showed by Gompertz’ model applied to numerous populations over time, the rate of increase
eγ in the hazard of mortality associated with ageing 1 year is approximately constant between
the ages of 50 and 95 (Brenner et al., 1993; Vaupel, 2010; Spiegelhalter, 2016), our target ages
for retirement. In this paper, we consulted the life table of 2010 of the United Kingdom to
calculate the annual rate of increase eγ in the hazard of mortality in the UK population (Ofﬁce
for National Statistics, 2017). The life tables are based on the population estimates and deaths
by date of registration data for a period of 3 consecutive years. The annual rate of increase eγ for
men and women between the ages 50 and 95 was approximately 1.107 and 1.115, respectively
(Figure 2). Subsequently, Δx number of years gained or lost in age due to the presence of risk
factor z is:
Δx=
logðeβzÞ
logðeγÞ 
βz
logð1:107Þ for men; and
Δx=
logðeβzÞ
logðeγÞ 
βz
logð1:115Þ for women:
This translation from hazard ratio to effective age could be used to explain to individuals the
consequences of various diseases and lifestyle choices and as a result persuade clients in life and
health insurance to pursue a healthier lifestyle.
Figure 1. Translating hazard of mortality to change in age
L. A. Gitsels et al.
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4. Period Life Expectancy
The period life table presents the period life expectation (LE) ex at age x, which is the weighted
average of the period life expectancies of people with different risk proﬁles at age x. Let ex,1 and ex,0
be the period life expectancies for people with and without the risk factor (reference subpopulation),
respectively, at age x. Then, the period life expectancy of the overall population ex at age x with its
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Figure 2. Log force of mortality for UK population based on 2010 period life table (Ofﬁce for
National Statistics, 2017)
Figure 3. Data selection for the heart attack study. Reproduced from Gitsels et al. (2017)
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prevalence of the risk factor px at age x is deﬁned as
ex = pxex;1 + 1pxð Þex;0: (1)
Changes in the prevalence of the risk factor px would result in changes in the period life expectancy
of the population ex at age x, ranging from ex,0 in the complete absence of the risk factor to ex,1 in the
complete presence of the risk factor.
When the proportional hazards assumption is satisﬁed, the overall (known) period LE ex can be
easily decomposed into the constituent LEs ex,1 and ex,0, which have known weights deﬁned by
prevalences. On the log-hazard scale, the constituent log forces of mortality can be drawn as parallel
curves which differ in intercepts deﬁned by one or more known parameters (the log-hazard ratios of
the risk factors and/or interventions). The shape of these curves is deﬁned by the baseline hazard
function μ0(x). Figures 4 and 5 depict these shapes for heart attack survivors and hypertensive
patients. The baseline log-hazard is simply a straight line if the Gompertz’ survival distribution
provides a good ﬁt. In this case, the only unknown parameter is the intercept for the reference log-
hazard rate, which can be derived from the equation (1). See Ashwell et al. (2014) and Li (2014) for
similar derivations on the impact of obesity and other lifestyle risk factors on life expectancy
assuming the Gompertz distribution.
In the following two sections, examples are given that illustrate how the hazard of mortality asso-
ciated with a risk factor is estimated in a sample of a population and how the estimated hazard of
mortality is translated to changes in life expectancies at the individual and population levels. The
implicit assumption of these calculations is that the shape of the baseline hazards (and therefore of
the survival functions generated by the survival model) in the sample of the population is the same as
that of in the full population of interest (which can be obtained from national period life tables if the
entire population is of interest). This assumption is vital for the generalisability of the results of
clinical studies to the underlying population.
5. Example on Treatment in Heart Attack Survivors
In a previous study, we estimated the hazard of mortality associated with a history of heart attack in
UK residents and how the survival prospects were changed by ﬁrst line treatments of heart attack
(Gitsels et al., 2017). In this example, we focus on the results on the recommended prescription of
beta blockers, which is a type of blood pressure treatment (National Institute for Clinical Excellence,
2013), in heart attack survivors, and translate these results to changes in life expectancies of heart
attack survivors at the individual and population levels. Coronary heart disease is the UK’s single
biggest killer, of which most deaths are caused by heart attack (British Heart Foundation, 2016). In
the United Kingdom, about seven out of 10 people survive a heart attack, resulting in almost two
million UK residents having survived a heart attack (Townsend et al., 2014).
In our study on heart attack (Gitsels et al., 2017), we selected data from The Health Improvement
Network (THIN) UK primary care database. This is a primary care database, which medical records
are representative of the UK population when adjusted for sex, age and deprivation (Hall, 2009; Blak
et al., 2011). The study design was a matched retrospective cohort study, where each patient with a
history of heart attack was matched to three controls on sex, year of birth, and clinic. We selected
four cohorts of patients who reached the target age between 1987 and 2011 and were followed-up to
2011. The target ages were 60, 65, 70, and 75, and their respective cohorts included 16,744, 43,528,
L. A. Gitsels et al.
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73,728, and 76,392 patients. The risk factor of interest was the prescription of beta blockers, which
across the target ages was prescribed in 44%–48% of the heart attack survivors. The outcome of
Figure 4. Log force of mortality in non-heart attack survivors (black), heart attack survivors
(blue), and heart attack survivors on beta blockers (green) by sex and age. Log force of mortality
adjusted for year of birth (reference of 1931–1935), deprivation (reference of “Alpha territory”
by Mosaic), lifestyle factors (reference of healthy), and medical history (reference of healthy).
Medical advances and future longevity
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Figure 5. Log force of mortality in hypertensive patients on standard treatment (black) and on
intensive treatment (blue) by sex and age. Log force of mortality adjusted for deprivation
(reference of 3rd Index of Multiple Deprivation quintile), lifestyle factors (reference of healthy),
and medical history (reference of healthy). Standard treatment has a systolic blood pressure target
of ≤140mmHg, whereas intensive treatment has a target of ≤120mmHg.
L. A. Gitsels et al.
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interest was time to death from any cause, which across the target ages was observed in 22%–24%
of the heart attack survivors who were prescribed beta blockers and in 33%–37% of the heart attack
survivors who were not prescribed the drugs. See Figure 3 for details of the data selection.
We estimated the hazard of all-cause mortality associated with the prescription of beta blockers by a
Cox’s proportional hazards regression and adjusted for sex, year of birth, deprivation, several heart
conditions including heart attack, chronic kidney disease, diabetes, high blood pressure, high choles-
terol level, heart surgery, prescription of “ﬁrst line” drugs to treat a heart attack, body mass index,
alcohol consumer status, smoking status, and clinic. All measurements were taken at the baseline target
age. We ﬁtted this survival model for each age cohort. The proportional hazards assumption was
assessed by Therneau & Grambsch’s test (2000) and indicated no violations.
Compared to no history of heart attack, a history of one heart attack by age 60, 65, 70, or 75 was
associated with an increased hazard of mortality of 1.80 (95% conﬁdence interval of 1.60–2.02), 1.71
(1.59–1.84), 1.50 (1.42–1.59), or 1.45 (1.38–1.53), respectively. In heart attack survivors, compared
to no prescription of beta blockers, a prescription of beta blockers by age 60, 65, 70, or 75 was
associated with a decreased hazard of mortality of 0.83 (0.73–0.94), 0.79 (0.73–0.85), 0.85 (0.81–
0.91), and 0.81 (0.77–0.86), respectively. In patients who did not have a history of heart attack,
prescription of beta blockers was not associated with a change in survival prospects. There were no
interaction effects between history of heart attack and sex or between prescription of beta blockers
and sex, indicating that the respective survival prospects were the same for men and women.
The hazard of mortality associated with a history of one heart attack by the target ages translated to
3.7–5.8 years gain in age (i.e. “ageing”) for a man and 3.4–5.4 years gain in age for a woman. This is
the change from the chronological to the effective age for a heart attack survivor. The hazard of
mortality associated with a prescription of beta blockers to a heart attack survivor by the target ages
translated to 1.6–2.3 years decrease in age (“rejuvenation”) for a man and 1.5–2.2 years decrease in
age for a woman. The change from the chronological to the effective age in a heart attack survivor
who is prescribed beta blockers is the sum of the number of years gained by a history of heart attack
and by a prescription of beta blockers. This means that a male or female heart attack survivor who is
prescribed beta blockers gained 1.6–3.9 years in age or 1.5–3.7 years in age, respectively.
The log forces of mortality were derived from the ﬁtted Cox’s proportional hazards regression that
was fully adjusted by the factors listed above. The baseline hazard rate (i.e. force of mortality in the
reference group) was derived from the cumulative baseline hazard rate estimated by the model. Then,
the baseline hazard rate was multiplied by the estimated hazard ratio of the risk factor of interest,
here heart attack, resulting in the force of mortality in heart attack survivors. Next, this hazard rate
was multiplied by the estimated hazard ratio of the intervention of interest, here beta blockers,
resulting in the force of mortality in heart attack survivors who were prescribed beta blockers.
Figure 4 depicts the log forces of mortality for the four age cohorts, men and women separately.
These are parallel curves that are approximately straight lines for ages 65 years and older. These
curves differ in intercepts deﬁned by the log-hazard ratios of the heart attack and of treatment by
beta-blockers in heart attack survivors, and by the intercept of the baseline risk curve. The shape of
these curves is deﬁned by the baseline hazard function μ0(x) (black line).
The overall period life expectancy of heart attack survivors can be calculated using the prevalence of
heart attack, the requisite hazard ratios, and the overall period life expectancy in the general
population. In the next step, the period life expectancies of heart attack survivors not prescribed beta
Medical advances and future longevity
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blockers and those prescribed beta blockers can be calculated using the prevalence of prescription of
beta blockers in heart attack survivors (Table 1), the requisite hazard ratios and the overall period
life expectancy of heart attack survivors (obtained from the previous step). Table 2 presents these
calculated period life expectancies at chronological ages 60, 65, 70 and 75 by sex.
Hypothetical changes in the overall life expectancy of heart attack survivors can be derived from
changes in the prevalence of prescription of beta blockers in this group. For example, if all men
surviving a heart attack by age 60 would be prescribed beta blockers, then their population life
expectancy would increase from 17.4 to 18.8 years, while if all would not be prescribed the drugs,
their population life expectancy would decrease to 16.4 years. Similarly, for women surviving a heart
attack by age 60, if all would be prescribed beta blockers, their population life expectancy would
increase from 20.3 to 21.8 years, while if all would not be prescribed the drugs, their population life
expectancy would decrease to 19.3 years.
Table 1. Prescription Level of Beta Blockers in Heart Attack Survivors in the
Age Cohorts
Men (%) Women (%)
Age 60 43 42
Age 65 46 43
Age 70 48 45
Age 75 47 44
Author’s computations.
Table 2. Period Life Expectancy for Heart Attack Survivors at 2010 Prescription Level of Beta Blockers and
Period Life Expectancies for Heart Attack Survivors With or Without Prescription of Beta Blockers
Sex Period Life Expectancy Age 60 (95% CI) Age 65 (95% CI) Age 70 (95% CI) Age 75 (95% CI)
Men All 22.03 18.03 14.33 11.00
Heart attack* 17.43
(17.32–18.32)
14.14
(13.62–14.64)
11.65
(11.28–12.00)
8.83
(8.54–9.11)
Prescription† 18.84
(17.9–19.85)
15.79
(15.27–16.37)
12.69
(12.25–13.01)
10.03
(9.68–10.33)
No prescription‡ 16.36
(16.89–17.16)
12.71
(12.20–13.16)
10.68
(10.38–11.07)
7.78
(7.54–8.03)
Women All 24.92 20.66 16.61 12.88
Heart attack* 20.33
(19.45–21.23)
16.67
(16.15–17.19)
13.80
(13.41–14.18)
10.56
(10.24–10.85)
Prescription† 21.76
(20.80–22.76)
18.39
(17.85–18.98)
14.91
(14.44–15.24)
11.85
(11.47–12.16)
No prescription‡ 19.29
(18.47–20.11)
15.35
(14.86–15.84)
12.90
(12.56–13.30)
9.53
(9.26–9.81)
The period life expectancies (95% conﬁdence intervals (CI)) are based on the UK life table centred 2009–2011
(Ofﬁce for National Statistics, 2017).
*Period life expectancy for heart attack survivors at 2010 prescription level of beta blockers. This period life
expectancy is the weighted average of the next two period life expectancies:
†Period life expectancy for heart attack survivors with prescription.
‡Period life expectancy for heart attack survivors without prescription.
L. A. Gitsels et al.
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6. Example on Treatment in People with High Blood Pressure
This example is about blood pressure treatment given to people with hypertension. A comparative
risk assessment of burden of disease and injury showed that high blood pressure is the number one
risk factor of global disease burden (Gakidou et al., 2017). The prevalence of high blood pressure,
deﬁned as a systolic blood pressure of 140mmHg or higher, is 32% in the United States and 30% in
the United Kingdom (British Heart Foundation, 2016; Whelton et al., 2017).
An inﬂuential US clinical trial named SPRINT examined the effect of lowering systolic blood pres-
sure to less than 120mmHg (intensive treatment) instead of to less than 140mmHg (standard
treatment) in patients with high blood pressure (SPRINT Research Group, 2015). The trial included
9,361 hypertensive patients aged 50–90 and had a median follow-up of 3.3 years. Half of the
patients were assigned the intensive treatment of blood pressure of whom 3.3% died from any cause
during the follow-up. In the standard treatment arm, death was observed in 4.5% of the patients.
Compared to the standard treatment of blood pressure, the intensive treatment was associated with a
decreased hazard of all-cause mortality of 0.73 (95% conﬁdence interval of 0.60–0.90) (SPRINT
Research Group, 2015). The annual mortality rate for men and women at ages 50–95 in the United
States in 2010 was approximately 1.092 and 1.098, respectively (Social Security Administration,
2014). This means that the intensive treatment of high blood pressure translated to the number of
years lost in age (“rejuvenation”) of 3.6 years in men and 3.4 years in women.
Recent evaluation of the research evidence on blood pressure thresholds for intervention by the
American Heart Association (AHA) (Whelton et al., 2017) and the Scottish Intercollegiate Guidelines
Network (SIGN, 2017) led to different updated hypertension guidelines. While the AHA changed its
hypertension guideline on the basis of SPRINT results (Whelton et al., 2017), the SIGN did not
because the trial was not regarded to be generalisable to the routine clinical practice in Scotland
mainly due to how blood pressure was measured (SIGN, 2017). Other reasons why the results might
not be generalisable to the general population are the trial’s restricted inclusion criteria of patients
and the trial’s short follow-up of patients. The question remains what the optimal blood pressure is
in people treated for hypertension in routine clinical practice. For this reason, we estimated the long-
term survival prospects associated with the intensive treatment of blood pressure in hypertensive
patients who were seen in primary care in the United Kingdom (Gitsels et al., 2018).
We selected data of THIN database. The study design was a retrospective cohort study. The sample
included 54,683 patients who were treated for hypertension between 2005 and 2013 and followed-
up to 2017. Patients had their systolic blood pressure dropped from more than 140mmHg (baseline)
to between 121 and 140mmHg (standard treatment) or to 120mmHg or less (intensive treatment).
At baseline, patients were between 50 and 90 years old. The risk factor of interest was intensive
treatment of blood pressure, which was observed in 36% of the patients. The outcome of interest
was time to death from any cause, which was observed in 13% of the patients on the intensive
treatment and 11% of the patients on the standard treatment. See Table 3 for details.
We estimated the hazard of all-cause mortality associated with the intensive treatment of blood
pressure by a Cox’s proportional hazards regression and adjusted for the number of anti-
hypertensive drugs prescribed at the baseline, the change in the number of anti-hypertensive drugs
prescribed at the dropped blood pressure measurement, prescription of several other drugs at
baseline, history of cardiovascular disease at baseline, sex, age at baseline, deprivation at baseline,
smoking status at baseline, and clinic. The proportional hazards assumption was assessed by
Medical advances and future longevity
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Therneau & Grambsch’s test (2000) and the effect of a violated risk factor was made time-
dependent.
Compared to the standard blood pressure treatment, the intensive treatment was associated with an
increased hazard of mortality of 1.21 (95% conﬁdence interval of 1.15–1.27). Thus, the intensive
treatment appears to be harmful, contradicting the SPRINT ﬁndings. There were no interaction
effects between blood pressure treatment and sex or age, indicating that the effect of intensive
treatment associated with the hazard of mortality was the same for men and women and across ages.
As the studied cohort included only hypertensive patients, the hazard of mortality associated with
hypertension could not be estimated. This hazard is needed to calculate the overall period life
expectancy of people with hypertension and the resulting period life expectancies of people on
intensive blood pressure treatment and of people on standard blood pressure treatment. Therefore,
we additionally selected four cohorts who reached the target age between 1987 and 2011 and were
followed-up to 2011. The target ages were 60, 65, 70, and 75, and each age cohort included between
140,000 and 350,000 patients. The selection of the target age cohorts was similar to that for the
heart attack study given in Figure 3, and was not the matched study design as with the heart attack
study. The risk factor of interest was hypertension, which across the target ages was observed in
63%–76% of the patients. The outcome of interest was time to death from any cause, which across
Table 3. Characteristics of The Health Improvement Network (THIN) Cohort of Hypertensive Patients
THIN
Standard Treatment Intensive Treatment
Number of participants 34,927 19,756
Total person-years follow-up (mean) 270,937 (7.8) 142,939 (7.2)
Deaths during follow-up 3,792 (11%) 2,519 (13%)
Chronic kidney disease
during follow-up
5,039 (14%) 3,139 (16%)
Systolic blood pressure at baseline Mean (s.d.) 158.7 (9.9) 155.8 (9.7)
Number of anti-hypertensive drugs at baseline 1 7,680 (22%) 5,095 (26%)
2 5,336 (15%) 4,044 (20%)
3 + 3,743 (11%) 3,128 (16%)
Change in number of anti-hypertensive drugs at entry More 25,160 (72%) 12,695 (64%)
Less 4,738 (14%) 3,447 (17%)
Aspirin Yes 4,851 (14%) 4,165 (21%)
Statin Yes 6,916 (20%) 6,087 (31%)
Cardiovascular disease Yes 1,216 (3%) 1,099 (6%)
Sex Male 17,909 (51%) 9,122 (46%)
Age Mean (s.d.) 64.6 (9.2) 65.1 (9.7)
Deprivation quintile 2 8,192 (23%) 4,439 (22%)
3 7,809 (22%) 4,329 (22%)
4 6,596 (19%) 3,878 (20%)
5 least 4,386 (13%) 2,706 (14%)
Smoking status Ex 11,915 (34%) 7,188 (36%)
Yes 6,272 (18%) 3,431 (17%)
Standard treatment of lowering systolic blood pressure to ≤140mmHg and intensive treatment of lowering
systolic blood pressure to ≤120mmHg.
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the target ages was observed in 16%–21% of the hypertensive patients and in 12%–19% of the
normotensive patients. We estimated the hazard of all-cause mortality associated with hypertension
by a Cox’s proportional hazards regression and adjusted for sex, deprivation, and clinic. We ﬁtted
this survival model for each age cohort. The proportional hazards assumption was assessed by
Therneau & Grambsch’s test (2000) and indicated no violations.
Compared to no hypertension, hypertension by age 60, 65, 70, or 75 was associated with a hazard of
mortality of 1.28 (95% conﬁdence interval of 1.24–1.33), 1.19 (1.16–1.22), 1.06 (1.04–1.09), or
0.96 (0.94–0.98), respectively. There were no interaction effects between hypertension and sex,
indicating that the effect of hypertension associated with the hazard of mortality was the same for
men and women.
The hazard of mortality associated with hypertension by the target ages translated to −0.4 to 2.4
years ageing for a man and −0.4 to 2.3 years ageing for a woman. This is the change from the
chronological to the effective age for a person with hypertension. The hazard of mortality associated
with intensive blood pressure treatment translated to 1.8 or 1.7 years ageing in a man or woman
with high blood pressure, respectively. The change from the chronological to the effective age in a
person with hypertension and on intensive blood pressure treatment is the sum of the number of
years added by hypertension and by intensive blood pressure treatment. This means that a man or
woman with hypertension who is on intensive blood pressure treatment was effectively older by 1.4–
4.2 years or 1.3–4.0 years, respectively.
For the data set described in Table 3, the log forces of mortality were derived from the ﬁtted Cox’s
proportional hazards regression that was fully adjusted by the factors listed above. The baseline
hazard rate (i.e. force of mortality in the reference group of hypertensive patients on standard
treatment) was derived from the cumulative baseline hazard rate estimated by the model. Then, the
baseline hazard rate was multiplied by the estimated hazard ratio of the intervention of interest, here
intensive treatment, resulting in the force of mortality in hypertensive patients on intensive treatment.
Figure 5 depicts the log-force of mortality for THIN hypertensive patients with or without intensive
blood pressure control at four retirement ages, men and women separately. Here the shape is initially
linear but then the baseline hazards are tapering down after 8 years of follow-up. Similar shapes are
familiar to demographers and actuaries in application to the mortality in older old people. This
perhaps may be explained by the high heterogeneity of hypertensive patients as suggested by
Wachter (2003). The frailest patients may be dying out early, and the survivors to older ages may be
a special group of ﬁt individuals. The heterogeneity may also be an explanation of the difference
between our results based on THIN data with SPRINT results.
Table 4. Prevalence of the Intensive Treatment of Blood Pressure in the
Study Sample
Men (%) Women (%)
Age 60 32 36
Age 65 33 36
Age 70 32 35
Age 75 41 39
Author’s computations.
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The overall period life expectancy of hypertensive people can be calculated using the prevalence of
hypertension, the requisite hazard ratios, and the overall period life expectancy in the general
population. In the next step, the period life expectancies of hypertensive people on standard blood
pressure treatment and those on intensive blood pressure treatment can be calculated using the
prevalence of intensive blood pressure treatment in hypertensive people (Table 4), the requisite
hazard ratios and the overall period life expectancy of hypertensive people (obtained from the
previous step). Table 5 presents these calculated period life expectancies at chronological ages 60, 65,
70 and 75 by sex.
Hypothetical changes in the population life expectancy of people with hypertension can be derived
from changes in the prevalence of intensive blood pressure treatment. For example, if all men with
hypertension at age 60 would be on the intensive blood pressure treatment, then their population life
expectancy would decrease from 20.0 to 18.6 years, while if all would be on the standard blood
pressure treatment, their population life expectancy would increase to 20.7 years. Similarly, for
women with hypertension at age 60, if all would be on the intensive blood pressure treatment, their
population life expectancy would decrease from 23.0 to 21.5 years, while if all would be on the
standard blood pressure treatment, their population life expectancy would increase to 23.8 years.
7. Comment About Using Estimated Hazards from Medical Studies
One should be cautious in taking estimated hazards of mortality in medical studies at face value and
translating them directly to life expectancies at the individual and population levels. As was shown in
the last example, the SPRINT clinical trial estimated a decrease in effective age of 3.4–3.6 years in
hypertensive patients due to the intensive blood pressure treatment compared to the standard blood
pressure treatment. Given the public health impact of the recent AHA guidelines, this would predict a
Table 5. Period Life Expectancy for People With High Blood Pressure at 2010 Prevalence of Intensive Blood
Pressure Treatment and Period Life Expectancies for People with High Blood Pressure on Intensive or Standard
Treatment
Sex
Period Life
Expectancy Age 60 (95% CI) Age 65 (95% CI) Age 70 (95% CI) Age 75 (95% CI)
Men All 22.03 18.03 14.33 11.00
Hypertension* 20.04 (19.77–20.32) 16.71 (16.52–16.90) 13.92 (13.77–14.06) 11.25 (11.12–11.38)
Intensive
treatment†
18.62 (18.19–19.01) 15.38 (14.98–15.75) 12.70 (12.33–13.03) 10.14 (9.80–10.44)
Standard
treatment‡
20.70 (20.50–20.92) 17.35 (17.26–17.45) 14.49 (14.45–14.54) 12.01 (12.02–12.03)
Women All 24.92 20.66 16.61 12.88
Hypertension* 22.95 (22.67–23.22) 19.33 (19.14–19.52) 16.19 (16.04–16.34) 13.14 (13.00–13.28)
Intensive
treatment†
21.53 (21.09–21.93) 17.97 (17.55–18.35) 14.91 (14.53–15.27) 11.96 (11.60–12.28)
Standard
treatment‡
23.76 (23.57–23.96) 20.10 (20.04–20.18) 16.88 (16.85–16.91) 13.89 (13.89–13.91)
The period life expectancies (95% conﬁdence intervals (CI)) are based on the UK life table centred 2009–2011
(Ofﬁce for National Statistics, 2017).
*Period life expectancy for people with high blood pressure at 2010 prevalence of intensive blood pressure
treatment. This period life expectancy is the weighted average of the next two period life expectancies:
†Period life expectancy for people with high blood pressure on intensive treatment.
‡Period life expectancy for people with high blood pressure on standard treatment.
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considerable boost to the life expectancy in the United States. In contrast, our observational cohort
study estimated an increase in effective age of 1.7–1.8 years in hypertensive patients due to the
intensive blood pressure treatment. This well may be due to the high heterogeneity of the general
population. Medical studies should be evaluated on the reliability and generalisability of the results
to the general population before translating the estimated hazards of mortality to changes in life
expectancy. Examples that could affect the reliability and generalisability of the results are the
selection criteria of the sample, the sample size, the length of follow-up, the measurement of risk
factors, the presence of confounding risk factors, and the appropriateness of statistical methods.
8. Conclusion
This paper demonstrated how hazards of mortality can be translated to life expectancies at the
individual and population levels. The information needed to calculate these life expectancies is the
hazard of mortality associated with the risk factor of interest, the prevalence of the risk factor of
interest, and a life table of the underlying population.
In both examples, hypothetical changes in the subpopulation life expectancy were derived from
changes in the prevalence of the health conditions and/or interventions of interest. So the assump-
tions need to be made only about possible trends in prevalence, as the magnitude of an effect of a
disease or a treatment on life expectancy would be already established from the described analysis.
In this vein, in the beta blockers example, hypothetical changes in the overall life expectancy of heart
attack survivors were derived from changes in the prevalence of prescription of beta blockers in this
group. For example, if all men surviving a heart attack by age 60 were to be prescribed beta blockers,
then their population life expectancy would increase from 17.4 to 18.8 years, while if none were
prescribed the drugs, their population life expectancy would decrease to 16.4 years. But if the
prescription rate is assumed to increase, say, to 80% (a more realistic assumption), then their
population life expectancy would increase from 17.4 to 18.3 years. Similarly, for women surviving a
heart attack by age 60, if all were prescribed beta blockers, their population life expectancy would
increase from 20.3 to 21.8 years, while none were prescribed the drugs, their population life
expectancy would decrease to 19.3 years. At 80% prescription, their population life expectancy
would increase to 21.1 years.
In this Research Programme, funded by the Actuarial Research Centre, we have already investigated
changes in life expectancy to do with statins (Gitsels et al., 2016), various heart attack treatments
(Gitsels et al., 2017) and alternative blood pressure targets (Gitsels et al., 2018). We have also started
work on (1) diabetes, one of the main killers of the 21st century, (2) stroke, which can have great
implications for life, health and long-term care insurance, and (3) hormone replacement therapy, an
intervention which greatly affects lifestyle, morbidity and possibly longevity of the female
population.
Changes in the prevalence of the risk factor of interest are reﬂected in the life expectancy at the
population level. From this, it can be calculated how much the risk factor of interest has already
contributed in changes in past longevity improvements and how continuing trends of the prevalence
of the risk factor of interest can affect future life expectancy. These calculations can be informative
for mortality projections of populations of insureds and pension schemes.
Medical advances and future longevity
15
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1357321719000059
Downloaded from https://www.cambridge.org/core. UCL, Institute of Education, on 24 Jun 2019 at 14:35:33, subject to the Cambridge Core terms of use, available at
Allowing for changes in prevalence in known treatments (e.g. anti-hypertensive prescriptions) and
differences in other factors (e.g. socioeconomic status) will never provide a complete answer,
however, especially when projecting future mortality improvements. It is a useful tool, though, that
can also help with questions like: “What would be the impact of another medical advance the size of
statins?”
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